

IN THE CLAIMS:

Amend the claims as follows.

Claims 1-38 (Canceled).

39. (New) A pharmaceutical package comprising a first container and a second container,

said first container comprising an antibody molecule conjugated to a first lipase component having a first lipase activity, and

said second container comprising a liposome containing at least one pharmaceutically active compound and a second lipase component having a second lipase activity,

said first lipase component and said second lipase component reconstituting to form a third lipase component having a third lipase activity, said third lipase activity being greater than the sum of said first lipase activity and said second lipase activity,

wherein at least one of said first lipase component or said second lipase component is an N-terminal recombinant *Clostridium perfringens* α -toxin (N-CPAT) and a C-terminal recombinant *Clostridium perfringens* α -toxin (C-CPAT),

said third lipase activity being sufficient to release said at least one pharmaceutically active compound from said liposome when said third lipase component is contacted with said liposome.

40. (New) The pharmaceutical package of claim 39 wherein said first lipase component is an N-CPAT and said second lipase component is a C-CPAT, and said N-CPAT and said C-CPAT are capable of combining to form said third lipase component.

41. (New) The pharmaceutical package of claim 39 wherein said second lipase component is an N-CPAT and said first lipase component is a C-CPAT, and said N-CPAT and said C-CPAT are capable of combining to form said third lipase component.

42. (New) The pharmaceutical package of claim 39 wherein said antibody molecule specifically binds to a target selected from the group consisting of an antigen, an antigen presenting target cell and a nucleotide sequence.

43. (New) The pharmaceutical package of claim 42 wherein said antigen presenting target cell is a tumor cell.

44. (New) The pharmaceutical package of claim 39 wherein said pharmaceutically active compound is selected from the group consisting of a chemotherapeutic cytotoxic agent, a lymphokine, an anti-inflammatory agent, an anti-fungal agent, and an anti-malaria agent.